Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

RALOXON FILM-COATED TABLETS 60 MG [SIN14013P]

Active ingredients: RALOXIFENE HYDROCHLORIDE (EQV. TO RALOXIFENE FREE BASE 56 MG)

View product's general information
Last updated on 9 October 2026

Product Info

RALOXON FILM-COATED TABLETS 60 MG

[SIN14013P]

Product information

Active Ingredient and Strength

RALOXIFENE HYDROCHLORIDE (EQV. TO RALOXIFENE FREE BASE 56 MG) - 60 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

PHARMATHEN S.A. - GREECE
PHARMATHEN INTERNATIONAL S.A. - GREECE

Registration Number

SIN14013P

Licence Holder

NOVEM PHARMA PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

G03XC01

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1. Therapeutic indications
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
For those postmenopausal women taking raloxifene for osteoporosis treatment, Raloxifene has been to shown to reduce the risk of invasive breast cancer.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see Section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Dosing

4.2. Posology and method of administration
The recommended posology is one tablet daily by oral administration, which may be taken at any time of the day without regard to meals. No dose adjustment is necessary for the elderly. Due to the nature of this disease process, raloxifene is intended for long term use.

Generally calcium and vitamin D supplements are advised in women with a low dietary intake.

Contraindications

4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients.

Must not be used in women with child bearing potential.

Active or past history of venous thromboembolic events (VTE), including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.

Hepatic impairment including cholestasis.

Severe renal impairment.

Unexplained uterine bleeding.

Raloxifene should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.